110 related articles for article (PubMed ID: 9433779)
41. (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-[125I]iodo- 2-methoxybenzamide hydrochloride, a new selective radioligand for dopamine D-2 receptors.
de Paulis T; Janowsky A; Kessler RM; Clanton JA; Smith HE
J Med Chem; 1988 Oct; 31(10):2027-33. PubMed ID: 3172140
[TBL] [Abstract][Full Text] [Related]
42. Effect of a series of 5-HT4 receptor agonists and antagonists on steroid secretion by the adrenal gland in vitro.
Contesse V; Hamel C; Delarue C; Lefebvre H; Vaudry H
Eur J Pharmacol; 1994 Nov; 265(1-2):27-33. PubMed ID: 7883026
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
Cohen ML; Bloomquist W; Gidda JS; Lacefield W
J Pharmacol Exp Ther; 1989 Jan; 248(1):197-201. PubMed ID: 2521513
[TBL] [Abstract][Full Text] [Related]
44. Central 5-HT3 receptors in P and in AA alcohol-preferring rats: An autoradiographic study.
Ciccocioppo R; Ge J; Barnes NM; Cooper SJ
Brain Res Bull; 1998 Jul; 46(4):311-5. PubMed ID: 9671260
[TBL] [Abstract][Full Text] [Related]
45. Nerve growth factor induces 5-HT3 recognition sites in rat pheochromocytoma (PC12) cells.
Gordon JC; Rowland HC
Life Sci; 1990; 46(20):1435-42. PubMed ID: 2345488
[TBL] [Abstract][Full Text] [Related]
46. Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]RS-42358-197.
Wong EH; Bonhaus DW; Wu I; Stefanich E; Eglen RM
J Neurochem; 1993 Mar; 60(3):921-30. PubMed ID: 8436978
[TBL] [Abstract][Full Text] [Related]
47. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
[TBL] [Abstract][Full Text] [Related]
48. Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain.
Fletcher S; Barnes NM
Brain Res; 1996 Aug; 729(2):281-4. PubMed ID: 8877001
[TBL] [Abstract][Full Text] [Related]
49. Immunolabeling of the rat central nervous system with antibodies partially selective of the short form of the 5-HT3 receptor.
Doucet E; Miquel MC; Nosjean A; Vergé D; Hamon M; Emerit MB
Neuroscience; 2000; 95(3):881-92. PubMed ID: 10670455
[TBL] [Abstract][Full Text] [Related]
50. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus.
Young R; Glennon RA
Eur J Pharmacol; 1992 Feb; 212(1):117-9. PubMed ID: 1555633
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, in vitro binding, and tissue distribution of radioiodinated 2-[125I]N-(N-benzylpiperidin-4-yl)-2-iodo benzamide, 2-[125I]BP: a potential sigma receptor marker for human prostate tumors.
John CS; Gulden ME; Li J; Bowen WD; McAfee JG; Thakur ML
Nucl Med Biol; 1998 Apr; 25(3):189-94. PubMed ID: 9620622
[TBL] [Abstract][Full Text] [Related]
52. The differential activities of R (+)- and S(-)-zacopride as 5-HT3 receptor antagonists.
Barnes JM; Barnes NM; Costall B; Domeney AM; Johnson DN; Kelly ME; Munson HR; Naylor RJ; Young R
Pharmacol Biochem Behav; 1990 Dec; 37(4):717-27. PubMed ID: 2128757
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
[TBL] [Abstract][Full Text] [Related]
54. Discrimination in 5-HT(3) receptor binding in murine brain and cultured cell preparations.
Zhang ZJ; Trivedi BL; de Paulis T; Schmidt DE; Hewlett WA
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):123-32. PubMed ID: 11819030
[TBL] [Abstract][Full Text] [Related]
55. A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
Hirokawa Y; Morie T; Yamazaki H; Yoshida N; Kato S
Bioorg Med Chem Lett; 1998 Mar; 8(6):619-24. PubMed ID: 9871571
[TBL] [Abstract][Full Text] [Related]
56. High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats.
Katayama K; Asano K; Haga K; Fukuda T
Jpn J Pharmacol; 1997 Apr; 73(4):357-60. PubMed ID: 9165374
[TBL] [Abstract][Full Text] [Related]
57. Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
Langlois A; Pascaud X; Junien JL; Dahl SG; Rivière PJ
Eur J Pharmacol; 1996 Dec; 318(1):141-4. PubMed ID: 9007525
[TBL] [Abstract][Full Text] [Related]
58. Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride.
Barnes NM; Costall B; Ironside JW; Naylor RJ
J Pharm Pharmacol; 1988 Sep; 40(9):668. PubMed ID: 2907045
[No Abstract] [Full Text] [Related]
59. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
60. Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P.
Emerit MB; Riad M; Fattaccini CM; Hamon M
J Neurochem; 1993 Jun; 60(6):2059-67. PubMed ID: 7684066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
